Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes

Biomarkers can be defined  as “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers play an integral part in conducting clinical trials and treating patients. In most instances, they help medical practitioners, researchers, and regulatory officials make well-informed, scientifically sound decisions. More efficient discovery and use of biomarkers in the development of antidiabetes drugs will depend on advancing our understanding of the pathogenesis of diabetes and especially its macrovascular complications.  Methodological advances from other fields, especially oncology, are beginning to pave the way toward improved models of diabetes pathogenesis and biomarker discovery.

  • Prognostic biomarkers
  • Diabetic nephropathy biomarkers
  • Diabetes: Clinical trials and new biomarkers under development
  • Pharmacotherapy in treatment of diabetes
  • Inflammatory markers: Type 2 diabetes
  • New drug treatments and devices for diabetes: current research

Related Conference of Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes

Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes Conference Speakers